A video walks through retatrutide and how targeting GIP and glucagon alongside GLP-1 sets it apart from current drugs.
Recap by typeshit. Full story at YouTube.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Dr. Regina DePietro of MU Health Care says unapproved peptides sold for research lack the safety checks Ozempic went through, and suggests asking a doctor first.
Photos online users uploaded mostly matched what they reported, but over 65% on compounded semaglutide or tirzepatide called it the brand version, Medscape reports.
Loading…